Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion type Assertion NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_head.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion evidence source_evidence_literature NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion SIO_000772 24518603 NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion wasDerivedFrom befree-20150227 NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion wasGeneratedBy ECO_0000203 NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.